We are live on
!
Find out more
OM
Opaleye Management Portfolio holdings
AUM
$758M
1-Year Est. Return
124.8%
This Fund
S&P 500
This Quarter
Est. Return
+15.57%
1 Year Est. Return
+124.8%
3 Year Est. Return
+486.05%
5 Year Est. Return
+742.19%
10 Year Est. Return
+62,231.09%
AUM
$758M
AUM Growth
+$493K
(+0.07%)
Cap. Flow
-$40.4M
Cap. Flow
% of AUM
-5.33%
Top 10 Holdings %
Top 10 Hldgs %
61.52%
Holding
62
New
8
Increased
18
Reduced
13
Closed
9
Top Buys
| 1 |
UroGen Pharma
URGN
|
+$23.3M |
| 2 |
Disc Medicine
IRON
|
+$15.3M |
| 3 |
Perspective Therapeutics
CATX
|
+$14.7M |
| 4 |
MeiraGTx Holdings
MGTX
|
+$13.2M |
| 5 |
Q32 Bio
QTTB
|
+$4.95M |
Top Sells
| 1 |
Harrow
HROW
|
+$47.2M |
| 2 |
Rhythm Pharmaceuticals
RYTM
|
+$20.1M |
| 3 |
CG Oncology
CGON
|
+$17.9M |
| 4 |
Alkermes
ALKS
|
+$13.7M |
| 5 |
Ocular Therapeutix
OCUL
|
+$9.48M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BBOT
51
BridgeBio Oncology
BBOT
$705M
| $477K | 0.06% |
+53,282
| New | +$572K |
|
|
LBRX
52
LB Pharmaceuticals
LBRX
$930M
| $358K | 0.05% |
+14,506
| New | +$335K |
|
|
ADGM
53
Adagio Medical Holdings
ADGM
$12.8M
| $21.2K | ﹤0.01% |
18,444
| – | – |
|
|
54
Alkermes
ALKS
$8.47B
| – | – |
-490,000
| Closed | -$13.7M |
|
55
BridgeBio Pharma
BBIO
$16.3B
| – | – |
-18,319
| Closed | -$1.4M |
|
|
GBIO
56
DELISTED
Generation Bio
GBIO
| – | – |
-310,000
| Closed | -$1.76M |
|
57
Gossamer Bio
GOSS
$65.6M
| – | – |
-2,720,000
| Closed | -$8.43M |
|
58
Karyopharm Therapeutics
KPTI
$227M
| – | – |
-930,000
| Closed | -$6.84M |
|
|
RAPT
59
DELISTED
RAPT Therapeutics
RAPT
| – | – |
-150,000
| Closed | -$213K |
|
|
SLN
60
Silence Therapeutics
SLN
$447M
| – | – |
-78,926
| Closed | -$480K |
|
|
VTYX
61
DELISTED
Ventyx Biosciences
VTYX
| – | – |
-251,932
| Closed | -$2.27M |
|
62
Zymeworks
ZYME
$1.84B
| – | – |
-108,929
| Closed | -$2.87M |
|
Similar funds
WCFA
SIG
GWM
IAS
TVAMP
RFM
MWA
CFS